Senate Republican leaders, aiming to salvage efforts backed by President Donald Trump to dismantle the Obamacare law, unveiled revised healthcare legislation that lets insurers sell bare-bones policies and retains key taxes on the wealthy.

Republican senators trying to repeal Obamacare are forming consensus to keep some of the U.S. healthcare law’s taxes they long criticized, in hopes of delaying more drastic funding cuts, particularly to the Medicaid program for the poor and disabled.

House of Representatives Majority Leader Kevin McCarthy said it would be “very difficult” to accelerate the end of enrollment in the Obamacare Medicaid expansion, as some conservative members of his Republican Party have proposed.

Spending on Rx drugs for health plans created under the ACA increased in 2016 at a rate more than three times that of other commercial plans and most government-run plans managed by Express Scripts Holding.

President Donald Trump and Republicans in Congress said they will unveil plans to repeal and replace Obamacare, providing a timeframe for a legislative goal they have struggled with for weeks.

The Coalition for Healthcare Communication (CHC) summit in Washington, D.C., in late November provided an interesting postmortem of the 2016 election, and a look into the crystal ball by some of our industry’s most knowledgeable leaders. Fast-forward to February 2017, and the crystal ball is still pretty cloudy.

Tim Price was tapped as Secretary of Health and Human Services and Seema Verna will helm the Centers for Medicare and Medicaid Services per Senate approval.

Pfizer has agreed to pay $784.6 million to resolve allegations that Wyeth, which it acquired in 2009, underpaid drug rebates to Medicaid.

U.S. Republican presidential front-runner candidate Donald Trump on Wednesday unveiled proposals for reforming U.S. healthcare that included repealing Obamacare, allowing prescription drugs to be imported, and turning the Medicaid program for the poor into block grants to states. The plan also calls for the sale of health insurance plans across state lines, full deduction of […]

U.S. state Medicaid programs spent $1.3 billion before rebates in 2014 on Gilead Sciences’ new hepatitis C drugs to treat fewer than 2.4 percent of enrollees with the liver disease, according to a U.S. Senate investigation into pricing of the blockbuster medicines. In the latest salvo against high U.S. prices for important medicines, the 18-month […]